Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study

Hadjadj J., Canzian A., KARADAĞ Ö., Contis A., Maurier F., Sanges S., ...Daha Fazla

RHEUMATOLOGY, cilt.62, ss.341-346, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 62
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1093/rheumatology/keac332
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.341-346
  • Anahtar Kelimeler: Polyarteritis nodosa, biologics, tocilizumab, rituximab, TNF-alpha, blocker, SYSTEMIC-NECROTIZING-VASCULITIDES, MANAGEMENT
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives. To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN).